PlexBio Co., Ltd., established in May 2010 to designs, develops and manufactures of IVD products and instrumentations in ISO-certified facilities. To this date, PlexBio has expanded from its headquarters in Taipei, Taiwan to Jiangsu Province, China and has an Innovative Technology Center in San Francisco, USA. Currently, PlexBio is a listed company at Taiwan emerging stock market.
In order to address the issue of rising healthcare costs and an increasing range of available tests, it is crucial for clinical and research labs to consider the cost of labor, sample volume, time and maintenance when it comes to assay formats. Therefore, PlexBio aims to provide a cutting-edge multiplexing platform using patented Precision Image Code (π Code) MicroDisc technology to overcome this limitation.
Our π Code Microdisc technology is currently the largest multiplexing platform, capable of generating around 16,000 circular image patterns. Each image pattern corresponds to an individual target and can be detected simultaneously via advanced optical imaging and fluorescence analyzers. By using our multiplexing platform, we are able to offer highly sensitive and specific results with low sample volumes, which save time and labor.
Currently, PlexBio is researching and developing high-quality reagents focusing on companion diagnostics, early cancer detection, prenatal diagnostics and food safety testing with ultra-detection sensitivity and fully automated diagnostics instruments for high-throughput clinical needs. With our innovative technologies, PlexBio intends to revolutionize the IVD industry developments, placing PlexBio as the leading brand of global IVD market.
Industry
Biotechnology Research, Scientific Research and Development Services, Services
HQ Location
6F-1, No. 351, Yangguang Street, Neihu District,
Taipei, 11491, TW
Keywords
Multiplexing using π Code microdiscFunctional Recombinant proteiImmunoassay/Molecular assay kitsdiagnostic reagentvitro assayfluorescent labelingworkstation designedquality health carebiopsy assaysplatform oncology assays